MAGI1 inhibits interferon signaling to promote influenza A infection

• Published in: Frontiers in cardiovascular medicine Vol. 9; p. 791143
• Main Authors: Wang, Yin, Abe, Jun-Ichi, Chau, Khanh M, Wang, Yongxing, Vu, Hang Thi, Reddy Velatooru, Loka, Gulraiz, Fahad, Imanishi, Masaki, Samanthapudi, Venkata S K, Nguyen, Minh T H, Ko, Kyung Ae, Lee, Ling-Ling, Thomas, Tamlyn N, Olmsted-Davis, Elizabeth A, Kotla, Sivareddy, Fujiwara, Keigi, Cooke, John P, Zhao, Di, Evans, Scott E, Le, Nhat-Tu
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 23.08.2022
• Subjects: Cardiovascular Medicine; EC inflammation; IAV; interferon signaling; IRF3; MAGI1; MX1; MAGI1; interferon signaling; EC inflammation; IRF3; MX1; IAV
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2022.791143

We have shown that membrane-associated guanylate kinase with inverted domain structure-1 (MAGI1), a scaffold protein with six PSD95/DiscLarge/ZO-1 (PDZ) domains, is involved in the regulation of endothelial cell (EC) activation and atherogenesis in mice. In addition to causing acute respiratory disease, influenza A virus (IAV) infection plays an important role in atherogenesis and triggers acute coronary syndromes and fatal myocardial infarction. Therefore, the aim of this study is to investigate the function and regulation of MAGI1 in IAV-induced EC activation. Whereas, EC infection by IAV increases MAGI1 expression, MAGI1 depletion suppresses IAV infection, suggesting that the induction of MAGI1 may promote IAV infection. Treatment of ECs with oxidized low-density lipoprotein (OxLDL) increases MAGI1 expression and IAV infection, suggesting that MAGI1 is part of the mechanistic link between serum lipid levels and patient prognosis following IAV infection. Our microarray studies suggest that MAGI1-depleted ECs increase protein expression and signaling networks involve in interferon (IFN) production. Specifically, infection of MAGI1-null ECs with IAV upregulates expression of signal transducer and activator of transcription 1 (STAT1), interferon b1 (IFNb1), myxovirus resistance protein 1 (MX1) and 2'-5'-oligoadenylate synthetase 2 (OAS2), and activate STAT5. By contrast, MAGI1 overexpression inhibits mRNA and MX1 expression, again supporting the pro-viral response mediated by MAGI1. MAGI1 depletion induces the expression of MX1 and virus suppression. The data suggests that IAV suppression by MAGI1 depletion may, in part, be due to MX1 induction. Lastly, interferon regulatory factor 3 (IRF3) translocates to the nucleus in the absence of IRF3 phosphorylation, and IRF3 SUMOylation is abolished in MAGI1-depleted ECs. The data suggests that MAGI1 inhibits IRF3 activation by maintaining IRF3 SUMOylation. In summary, IAV infection occurs in ECs in a MAGI1 expression-dependent manner by inhibiting anti-viral responses including STATs and IRF3 activation and subsequent MX1 induction, and MAGI1 plays a role in EC activation, and in upregulating a pro-viral response. Therefore, the inhibition of MAGI1 is a potential therapeutic target for IAV-induced cardiovascular disease.